Entellus Medical, Inc., a medical technology company, focuses on the design, development, and commercialization of products for the minimally invasive treatment of patients suffering from chronic and recurrent sinusitis. The company offers XprESS Multi-Sinus Dilation family of products consisting of XprESS Pro device, XprESS LoProfile device, and XprESS Ultra device, which open an obstructed or narrowed drainage pathway of a sinus cavity by means of trans-nasal balloon sinus dilation. It also provides PathAssist tools, such as LED Light Fiber, a single-use tool that provides real-time high intensity red trans-illumination of the sinus cavity with its battery power; Light Fiber, a single-use ...
3600 Holly Lane North
Plymouth, MN 55447
Founded in 2006
Entellus Medical, Inc. Presents at Dougherty and Company Institutional Investor Conference, Sep-19-2017
Aug 7 17
Entellus Medical, Inc. Presents at Dougherty and Company Institutional Investor Conference, Sep-19-2017 . Venue: Millennium Hotel, 1313 Nicollet Mall, Minneapolis, Minnesota, United States.
Entellus Medical, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2017; Provides Earnings Guidance for the Third Quarter and Full Year of 2017
Aug 3 17
Entellus Medical, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, revenue was $22,140,000 compared with $18,730,000 a year ago. Net loss was $8,043,000 or $0.37 per basic and diluted share, compared with $5,021,000 or $0.27 per basic and diluted share, for the same period of the prior year. Loss from operations was $7,640,000 against $4,526,000 a year ago. The growth in revenue was attributable to increased sales of the company’s disposable products, including the XprESS family of products, as well as strong sales of capital products. Loss before income tax expense was $8,040,000 against $5,021,000 a year ago. Foreign currency exchange rates negatively impacted revenue by approximately $0.1 million for the quarter.
For the six months, the company reported revenue of $41,246,000 against $35,632,000 a year ago. Loss from operations was $15,471,000 against $10,892,000 a year ago. Net loss was $16,381,000 against $11,893,000 a year ago. Net loss per basic and diluted share was $0.77 against $0.63 a year ago. Loss before income tax expense was $16,375,000 against $11,893,000 a year ago.
The company expects third quarter 2017 revenue, inclusive of anticipated Spirox revenue, to be in a range of $22.8 million to $23.8 million, representing growth of 27% to 33% over third quarter 2016 revenue. Excluding the impact of purchase accounting, non-GAAP adjusted combined gross margin is expected to be in a range of 72% to 74% for the third quarter of 2017. Third quarter 2017 non-GAAP adjusted EBITDA, inclusive of Spirox operations, is expected to be in a range of negative $9.0 million to negative $11.0 million.
The company expects full year 2017 revenue, inclusive of anticipated Spirox revenue from July 13 through year end, to be in a range of $91.5 million to $94.5 million, representing growth of 22% to 26% over 2016 revenue. Excluding the impact of purchase accounting, non-GAAP adjusted combined gross margin is expected to be in a range of 72% to 74% for the full year 2017. Full year 2017 non-GAAP adjusted EBITDA, inclusive of Spirox operations, is expected to be in a range of negative $22.0 million to negative $26.0 million. In light of its new adjusted EBITDA guidance, and to assist with the modeling, the company provided reconciliations from reported net loss to non-GAAP adjusted EBITDA for the previous 6 quarters on its website. Additionally, to provide the further context, based on its previously provided and now superseded full year stand-alone Entellus net loss guidance range of $24 million to $32 million, the corresponding adjusted EBITDA was expected to be in the range of negative $11 million to negative $19 million.
Entellus Medical, Inc. Presents at Canaccord Genuity 37th Annual Growth Conference, Aug-09-2017 08:30 AM
Jul 26 17
Entellus Medical, Inc. Presents at Canaccord Genuity 37th Annual Growth Conference, Aug-09-2017 08:30 AM. Venue: Intercontinental Hotel, 510 Atlantic Ave, Boston, Massachusetts, United States.